Home › Compare › MKLNF vs ABBV
MKLNF yields 5.05% · ABBV yields 3.06%● Live data
📍 MKLNF pulled ahead of the other in Year 2
Combined, MKLNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MKLNF + ABBV for your $10,000?
M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty and Trade. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology, as well as trades in pharmaceutical, biosimilars, and other medical products and devices in the areas of oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. The company also engages in the acquisition, management, and sale of real estate, primarily in the health care sector. It offers its products to doctors, pharmacies, and wholesalers under the M1 Select brand. The company operates a network of outpatient specialist centers; and a specialized surgical clinic center, as well as 46 specialist centers under the M1 Med Beauty brand. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.
Full MKLNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.